Table 4.
NCBI rs# | Location | Variant | Genotype | Frequency | Allele-dose | Dominant* | Recessive# | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Without NIHL (-) | with NIHL (+) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | ||||
rs208679 | 5’flanking | A/G | AA | 99 (58.20) | 42 (62.70) | 0.13 | 1.41 (0.86~2.30) | 0.56 | 1.21 (0.67~2.16) | 0.046 | 6.39 (0.83~49.35) |
AG | 56 (32.90) | 24 (35.80) | |||||||||
GG | 15 (8.80) | 1 (1.50) | |||||||||
rs10836233 | 5’flanking | G/A | GG | 82 (48.50) | 35 (53.00) | 0.70 | 0.93 (0.60~1.44) | 0.82 | 1.16 (0.48~2.81) | 0.56 | 0.84 (0.47~1.48) |
GA | 69 (40.80) | 23 (34.80) | |||||||||
AA | 18 (10.70) | 8 (12.10) | |||||||||
rs2300182 | Intron1 | T/A | TT | 111 (65.30) | 40 (59.70) | 0.67 | 1.25 (0.77~2.03) | 0.51 | 1.48 (0.42~2.23) | 0.46 | 1.27 (0.71~2.27) |
TA | 52 (30.60) | 23 (34.30) | |||||||||
AA | 7 (4.10) | 4 (6.00) | |||||||||
rs769217 | exon9 (synon) | T/C | TT | 36 (21.20) | 16 (23.90) | 0.82 | 0.88 (0.59~1.32) | 1.00 | 0.96 (0.49~1.86) | 0.38 | 0.75 (0.38~1.45) |
TC | 90 (52.90) | 36 (53.70) | |||||||||
CC | 44 (25.90) | 15 (22.40) | |||||||||
rs7104301 | 3’flanking | A/G | AA | 103 (60.60) | 37 (55.20) | 0.69 | 0.82 (0.51~1.30) | 0.47 | 0.80 (0.45~1.42) | 0.51 | 0.68 (0.19~2.39) |
AG | 60 (35.30) | 26 (38.80) | |||||||||
GG | 7 (4.10) | 4 (6.00) | |||||||||
rs7949972 | 3’flanking | C/T | CC | 61 (35.90) | 19 (28.40) | 0.29 | 0.72 (0.48~1.08) | 0.23 | 0.68 (0.37~1.26) | 0.22 | 0.63 (0.33~1.23) |
CT | 78 (45.90) | 30 (44.80) | |||||||||
TT | 31 (18.20) | 18 (26.90) |
Dominant effect = variant homozygotes + heterozygotes versus wild-type homozygotes;
Recessive effect = variant homozygotes versus heterozygotes + wild-type homozygotes.